Clinical trial
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary…
NCT00005951 · Duke University, Other · Completed
Key facts
| NCT number | NCT00005951 |
|---|---|
| Title | Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma |
| Official title | Phase I Treatment of Adults With Primary Malignant Glioma With Irinotecan (CPT-11) (NSC- #6616348) Plus Temodar (NSC #362856) |
| Lead sponsor | Duke University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | irinotecan hydrochloride, temozolomide |
| Start date | Aug 1, 2000 |
| Primary completion | Apr 1, 2006 |
| Completion | Apr 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Aug 22, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: